Anders Hove has been with Venrock since 2004, applying his extensive knowledge in both venture capital and pharmaceutical operations to biotechnology companies at all stages. Anders also has primary responsibility for managing Venrock Healthcare Capital Partners. He currently serves on the Board of Directors of Anacor Pharmaceuticals (NASDAQ: ANAC) and World Heart Corp. (NASDAQ: WHRT), as well as several private company Boards, such as Intuity Medical, QuatRx Pharmaceuticals, Mevion Medical Systems, and Virdante Pharmaceuticals. Previous investments include Adnexus Therapeutics (acquired by Bristol-Myers Squibb), Eyetech Pharmaceuticals (acquired by OSI Pharmaceuticals), PEAK Surgical (acquired by Medtronic), The Medicines Company (NASDAQ: MDCO), Monogram Biosciences (acquired by Laboratory Corporation), Theravance (NASDAQ: THRX) and Third Wave Technologies (acquired by Hologic). In 2011, Anders was named to Forbes’ Midas List, which ranks the top venture capitalists in life sciences and technology.
Prior to Venrock, Anders held senior level positions in the medical, clinical and business operations of the pharmaceuticals division of Ciba-Geigy, and later as the portfolio manager of BB Biotech and CEO of Bellevue Asset Management. At Bellevue, Anders had responsibility for managing BB Biotech, an investment company with $1.6 billion invested in public and private biotech companies. While at BB Biotech, Anders led numerous public and private investments and BB Biotech was the largest shareholder in companies such as Alexion (NASDAQ: ALXN), Medimmune (acquired by Astra Zeneca) and Aviron (acquired by Medimmune).
Anders earned his M.Sc. in Biotechnology Engineering from the Technical University of Denmark, his M.D. at the University of Copenhagen and an M.B.A. from INSEAD.